FILTER
FILTERED INTERVIEW RESULTS
Robert K. Coughlin
PRESIDENT & CEO, MASSBIO
MassBio’s mission is to advance Massachusetts' leadership in life sciences to grow the industry, add value to the healthcare system and improve patient lives.
Jennifer Hawks Bland
CEO, NEWYORKBIO
NewYorkBIO brings together New York’s bioscience stakeholders to advance life science research and commercialization.
Eric Falcand
VICE PRESIDENT, HEAD OF BUSINESS DEVELOPMENT AND LICENSING, SERVIER GROUP
Servier is strengthening its oncology portfolio and widneing its U.S. footprint.
James Greenwood
PRESIDENT & CEO, BIOTECHNOLOGY INNOVATION ORGANIZATION
The Biotechnology Innovation Organization (BIO) represents biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
Doug Giordano
SENIOR VP, BUSINESS DEVELOPMENT, PFIZER
A look at the latest trends in business development from a global pharma powerhouse.
Scott Baker
CEO, TORNADO SPECTRAL SYSTEMS
Tornado Spectral Systems is a Toronto-based startup that designs, manufactures and sells dispersive optical spectrometers and systems for Raman spectroscopy.
Debbie Hart
PRESIDENT AND CEO, BIONJ
Founded in 1994, BioNJ’s mission is to enhance the climate for the life sciences industry in the state.
Arda Ural
PHD PARTNER & OPERATIONAL TRANSACTION SERVICES LIFE SCIENCES LEADER - TRANSACTION ADVISORY SERVICES, ERNST AND YOUNG (EY)
EY is a multinational professional services firm headquartered in London, United Kingdom.
Annette Grimaldi
MANAGING DIRECTOR, LIFE SCIENCES INVESTMENT BANKING, BMO CAPITAL MARKETS
Bassil Dahiyat
PRESIDENT AND CEO, XENCOR
Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2024 - Digital Interactive
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
